The purpose of this study is to learn more about the study drug called AG10 that may be helpful in treating Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM). We hope to find out how safe and effective the AG10 study drug is in people with ATTR-CM. The study will have two phases with a double-blind treatment for 31 months and an open label extension for 28 months. 

Feel free to contact our research team or your doctor for more information and to learn if you are eligible to be a part of the study. 

Principal Investigator:

Ahmad Masri

Study Coordinator:

Emilie Cohen

Feel free to contact the KCVI clinical trials team for any information regarding this trial or upcoming clinical trials. 

Phone: 503-418-1964